European Statistical Meeting
Oncology and Survival Analysis

09:30-17:00
Friday 17th November 2017
BMS, Brussels

Survival analysis methods, or 'Time to event' methods, are used in many clinical indications for the development, regulatory approval, and health technology assessment of new therapeutics. Originally developed to analyse trial endpoints in oncology, they are now used in many other indications.
This meeting aims to bring together statisticians from the pharmaceutical industry, academia and regulatory agencies to hear about recent advances in survival analysis methods and their application in oncology.

Confirmed speakers include

Michal Kicinsky and Nathan Touati EORTC	Statistical challenges in immunotherapy trials: EORTC's views
Everardo Saad IDDI	Surrogate endpoints in oncology: objectives, methodological overview, and current status
Federico Rotolo CESP INSERM	Multimarker-based subgroups in time-to-event randomized clinical trials
Gerd Rosenkranz Medical University of Vienna	Subgroup Identification via the Predicted Individual Treatment Effect
Julien Péron Lyon University	Generalized Pairwise Comparison on Immuno-Oncology clinical trial data: a case study"
Agnes Balogh BMS	Multiplicity Correction in a Group-Sequential Oncology Trial Including Subgroup Analyses and Multiple Primary Endpoints: a Case Study

The program will also include a panel discussion with the speakers and **Bertil Jonsson** (Medical Products Agency and EMA)

Venue

NV Bristol-Myers Squibb
Belgium SA
Parc de l'Alliance
Avenue de Finlande 4
B – 1420 Braine-l'Alleud
Belgium

Registration

Fee includes lunch & refreshments

On or before October 15th

Industry rate:	€170.00
Academic rate:	€110.00

After October 15th

Industry rate:	€200.00
Academic rate:	€130.00

To attend this meeting register your details at:

www.efspi.org

or contact

EFSPI Secretariat
Tel: +44 (0) 1625 664549
efspi@kingstonsmith.co.uk

For information regarding the scientific content contact:

emmanuel.quinaux@iddi.com or
francois.aubin@venncro.com